Posted by Michael Wonder on 29 Apr 2022
Agenda update for the May 2022 PBAC intracycle meeting
29 April 2022 - The agenda for the May 2022 PBAC intracycle meeting has been updated.
The following submissions have been added:
- Burosumab (Crysvita) - new medicine
- Daratumumab with hyaluronidase (Darzalex SC) - new indication
- Dulaglutide (Trulicity) - new formulation
- Pembrolizumab (Keytruda) - new indication
- Pregabalin (Lyrica CR, Pregagalin-AFT) - new formulation
The MAESTrO Database has been updated accordingly.
